The start-up behind a magic mushroom nose spray for psychedelic microdosing

The company claims the product is ready and waiting for legalization measures in the United States to pass over the coming years
The company claims the product is ready and waiting for legalization measures in the United States to pass over the coming years
VIEW 1 IMAGES

Predicting a wave of psychedelic legalization over the coming decade, Oregon-based start-up Silo Wellness has reportedly developed a magic mushroom nasal spray focused on delivering exact, controlled psychedelic microdoses via an easy inhaler. New Atlas contacted Silo Wellness founder and CEO Mike Arnold to learn more about how this bold product actually works.

Grassroots psychedelic activism

Alongside the rapidly progressing psychedelic science movement, with researchers rigorously exploring the medical and therapeutic uses of previously taboo psychoactive compounds, is a growing grassroots movement to decriminalize some of these substances. Across 2019 a number of different local jurisdictions in the United States began the first stages of decriminalizing psychedelic substances.

The movement ostensibly started with the passing of a ballot initiative in the City and County of Denver back in March. The publicly voted initiative essentially decriminalized the personal use and possession of magic mushrooms. Following that landmark moment, a number of other cities in the country have pushed forward similar measures.

The long game here is looking toward the 2020 US elections and getting a variety of measures on state ballots. There is debate among activists, however, over how broad a push there should be for recreational legalization. A proposed 2020 ballot measure filed in California is proposing full retail legalization of psilocybin magic mushrooms, while the current measure proposed in Oregon is not looking at commercial sales but instead focusing on legalizing therapeutic uses in licensed facilities.

Motivated by the explosive growth of business in the cannabis industry, as recreational legalization spreads across America, some entrepreneurs are looking at psilocybin as the next prospective drug to hit the broader market. One Denver-based company called Strava, for example, has already begun developing tea and coffee products infused with microdoses of psilocybin.

These products may not be legal right now, but many are preparing for legalization, readying commercial products to serve the whims of every kind of recreational consumer.

Why develop a magic mushroom nasal spray?

Silo Wellness is one of those aforementioned entrepreneurial start-ups, and it is working to develop a magic mushroom-based nasal spray. The idea behind the product is to offer people a way into the psychedelic experience using a controlled delivery device that can offer consistent regulated microdoses.

“We solved the age-old problem with plant- and fungus-based medicine: How do you know how much is a dose?” explains Michael Hartman, an experienced pharma product developer working with Silo Wellness. “How do you avoid taking too much, like the cannabis edibles dilemma? We also managed to solve one of the common complaints of some mushroom users: taste and upset stomach.”

The CEO and founder of Silo Wellness is former criminal attorney Mike Arnold, who left his law industry job to start a marijuana growing company back in 2016. After a life-changing magic mushroom experience in 2018, Arnold saw a hurdle in the movement to bring psychedelics into the mainstream. His first magic mushroom experience was fortunately one guided by a knowledgeable physician, who could offer a controlled dose, but what if that guided experience wasn’t available to someone?

Arnold saw the solution to the problem as a controlled nasal spray that administered a metered, fast-acting dose of magic mushrooms in a way that could ease less experienced individuals into the psychedelic experience.

The nasal spray being developed is not pure psilocybin, but instead, Arnold tells New Atlas is a, “full myco-spectrum extract of Jamaican magic mushrooms in an aqueous solution.”

The two factors the company is focusing its current research on are uptake speed and bioavailability. Arnold suggests the benefits of dosing through a nasal spray are a faster onset, reducing the delay in effect and decreasing the risk of consuming too much, and a reduction in some of the unpleasant nauseous effects of digesting mushrooms in the gut.

“We believe that the nasal track has greater bioavailability and faster uptake speed than going through the gut,” Arnold tells New Atlas. “Once the product is more widely available to the public, specific dosing will be disclosed; but, currently, one dose in each nostril has the biomass equivalent of no more than 0.1 grams. We are targeting a sub-psychedelic dose right now with a small psychedelic dose anticipated soon.”

The product is currently being developed in Jamaica, one of the only countries in the world where magic mushrooms are completely legal. Arnold suggests dose-ranging studies are underway in the island nation, and the company is initially focusing on a producing a product aimed at microdose-levels of magic mushrooms.

Of course, what constitutes a microdose in the world of psychedelic compounds?

What is a microdose?

The science is certainly still out over whether psychedelic microdosing confers real benefits or whether the technique is a glorified placebo, akin to psychedelic homeopathy. As scientists work to clinically verify the effects, and safety, of sustained tiny psychedelic drug doses, there is debate over how much of a dose actually constitutes a microdose.

Many would argue one has taken too much of a substance if they are actively feeling acute effects, and many microdosers suggest regular doses must be sub-perceptual. This means the subtle benefits of microdosing, relating to improved mood, energy or creativity, arise slowly over time.

Mike Arnold suggests the nasal spray his company is developing will center around microdoses, but not sub-perceptual microdoses. So the idea is you will feel some rapid acute effects from one or two sprays. He calls the dose “sub-psychedelic.”

“As a company, we do not pigeonhole microdosing into sub-perceptual levels,” Arnold tells New Atlas. “Many of us in the company have experimented personally with various levels of microdosing from sub-perceptual levels on up. It is very common anecdotally and it is within my own personal experience that a 0.1 gram on up to 0.25 gram level of biomass microdosing will give you various positive perceivable effects that is readily within grasp of personal research simply by trying microdosing at various sub-psychedelic levels.”

Silo Wellness is one of several ambitious startups looking ahead to a future of legalized recreational psychedelics. But, as evidenced by the variety of ballot initiatives coming up in 2020, there is little agreement in the psychedelic community over whether the movement should push for broad legalization, or a more limited decriminalization.

Legalization VS Decriminalization

Michael Pollan, author of the bestselling psychedelic science book How To Change Your Mind, summed up these divisions in an influential New York Times op-ed earlier in 2019 titled “Not So Fast on Psychedelic Mushrooms”.

Pollan’s general argument is that while psilocybin seems to be traveling a similar path to legalization as cannabis traversed, we should be clear in understanding they are two very different substances. He supports decriminalization of some psychedelic drugs, and enthusiastically promotes the growing medical and therapeutic uses being researched, but is concerned recreational legalization of psychedelics could be dangerous to unleash into a culture dominated by capitalist sentiment.

“I see cannabis being promoted and pushed to people, as capitalism will do,” Pollan said at an event in Melbourne in July. “When I come home from this trip on Monday and I cross through Bay Ridge from the airport to Berkeley, I’ll see three or four billboards for companies that can deliver cannabis to my home in two hours, and I just don’t think we know enough to legalize these [psychedelic] drugs.”

“We should take lessons from cultures that have been using psychedelics for thousands of years,” he said in July. “They’re always used in a very careful cultural container. They’re never used casually, people don’t take them alone, there’s always an elder involved and there’s always an intention involved … We haven’t devised that proper container and I think we need to do that before we legalize it.”

Mike Arnold on the other hand, is incredibly enthusiastic about making psychedelics as widely available as possible. He says legalization is inevitable, suggesting his dose-controlled nasal spray actually offers a technology that makes the broad legal roll-out of magic mushrooms much safer. He claims his product will allow new users to cautiously experiment with metered doses, allowing novice psychedelic users a way into the psychedelic experience without jumping into extreme “trip” sessions.

“Oregon is on track to pass its psilocybin initiative petition in the fall of 2020,” Arnold says. “We expect it to pass given it was polling at 64% before mainstream media really picked up on the psychedelic medicine movement. Legalization is inevitable. We expect the states to fall like dominoes thereafter, much like cannabis but with a much more compressed timeline. The first state to decriminalize cannabis was Oregon’s “less than an ounce” law back in the 1970s, yet it took another 20 years to have California pass medical. Now within a year of Denver decriminalizing we can expect the first state to go legal. That timeline is mind-blowing.”

Scientific research with therapeutic outcomes is certainly progressing fast, and both psilocybin and MDMA have been awarded Breakthrough Therapy status from the FDA, but it is clear segments of the general public are becoming impatient with the slow pace of medical trials. It is possible by 2025 both psilocybin and MDMA could be FDA-approved medicines, available in clinical environments for a variety of conditions. But separate to those pathways, magic mushrooms are particularly being pushed for more general legalization through local initiatives. However the next few years play out, there seems to be several start-ups ready to jump into the market with psychedelic products as soon as they become legal.

“This isn’t a ‘plan’ to develop a product or a ‘plan’ to open a facility,” explains Michael Hartman, who is working on the aerosol technology Silo Wellness is using. “We have real proof of concept and continued research and development underway — not just an idea. We have developed this and have already received user testimonials. We have been in the space for over a year planning this. The future is now and we are ready.”

Source: Silo Wellness

World’s first magic mushroom nasal spray for PTSD and depression

World’s first magic mushroom nasal spray for PTSD and depression
© iStock/Deagreez

PTSD and depression are two conditions that are being trialled for treatment with psilocybin.

A ‘magic mushroom’ nasal spray has been designed to make microdosing easier for people trying to treat their PTSD or depression.

Silo Wellness, an Oregon company with a team with roots in cannabis delivery modalities, has developed a magic mushroom nasal spray in Jamaica – where psilocybin is legal – for controlled, metered-dosing known as ‘microdosing’.

Magic mushroom nasal spray

The psilocybin nasal spray passes the gut, going directly to the bloodstream through the nasal mucus membranes and eventually the liver for metabolising. This saves the patient from feeling nauseous, as commonly experienced when taking psilocybin.

Board Advisor and Silo Wellness investor Becky Rotterman, a Missouri pharmacist, stated: “Many psilocybin patients, particularly women, complain of upset stomach or vomiting when taking high-doses of mushrooms.

“We want to bring this wonderful natural medicine first to Oregon and then the flyover states – to those who would be afraid to eat a handful of fungi and who feel more comfortable seeing their medicine in a familiar delivery modality, such as a metered-dose nasal spray.”

The correct dose

When a patient takes psilocybin the dosage is vital. Many people end up ‘stacking’, whereby the first dose takes some time to take effect so the patient consumes more, only to find they have taken too much later on. Microdosing alternatives with faster uptake speed are important  in order to prevent accidental high-dosage experiences.

Silo Wellness founder, Mike Arnold, said he created the medicine dispenser after his first experience with psilocybin after he was advised by a doctor to try it.

He said: “I couldn’t help to think how fortunate I was to have an actual physician take me on my first trip rather than ‘some guy’ I know, but I realised that most first-time users don’t have that luxury.

“I reached out to my long-time colleague from the marijuana space, brilliant inventor Michael Hartman, and we agreed that we need to be able to give patients predictable dosing so they can self-titrate into the desired levels of sub-psychedelic or psychedelic treatment.”

“We solved the age-old problem with plant- and fungus-based medicine: How do you know how much is a dose?” Hartman explained. “How do you avoid taking too much, like the cannabis edibles dilemma? We also managed to solve one of the common complaints of some mushroom users: taste and upset stomach.”

Healing trauma with magic mushrooms

Psilocybin is being trialled for the treatment of a number of physical and mental conditions, two of which are PTSD and depression. The psychoactive component is thought to stimulate receptors in the brain and potentially ‘rewire the brain’ by increasing neuro connectivity – helping to heal trauma from physical or psychological events.

COO, Scott Slay, said: “We are so grateful for the opportunity to have an actual and real first-to-market consumer product in magic mushrooms.

“I found mushrooms after returning from Iraq working in IED demolition and combat. The war changed me and the VA was ill equipped to help me transition and deal with my PTSD.

“I was heavily medicated. Mushrooms and DMT saved me. My life was renewed. I now have peace and purpose, and I can’t wait to share this opportunity with the world.”

Since psilocybin and other psychoactive compounds are found in nearly 200 known-species of mushrooms, humans have evolved around these beneficial chemical compounds.

Users of psychedelics have known for many years that small “micro doses” of mushrooms can give the user spiritual, medical, and therapeutic benefits without sending the user into a psychedelic ’trip’ as with high doses of mushroom biomass.

Psilocybin for depression has recently been given its second ‘Breakthrough Therapy’ designation by the FDA.

BETTER PLANT’S HAND SANITIZER GEL APPROVED FOR LISTING ON AMAZON.COM

Vancouver, B.C. – October 6, 2020: Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) or (the “Company”) is pleased to announce that Amazon.com has approved the listing for its hand sanitizer gel, which is manufactured by its subsidiary, Urban Juve. The hand sanitizer gel is listed with the FDA (NDC 75385-0010-1) and has received Natural Health Product Number 80098154 from Health Canada. Urban Juve’s Ultra Hydrating Hand Sanitizer Spray received Health Canada approval on March 27, 2020. The Hand Sanitizer Gel will be live on Amazon.com later this month. Both the Hand Sanitizer Gel and Spray are available for purchase on Amazon.ca and urbanjuve.com.

“The popularity of Amazon is undeniable”, says Gabe Villablanca, Better Plant’s Director of eCommerce. “During these times, it is becoming more and more simple and stress-free to shop online, so we want to expand that accessibility across the top platforms.” Earlier this year, Urban Juve’s full line went live on Amazon.ca, offering free shipping on orders over $35. Due to high demand, Urban Juve ensured the Hand Sanitizer Gel was the first product to be pushed through the approval process for Amazon.com. The Company plans to continue to use data to guide where they will make products available online for the convenience of consumers.

Based on a survey of more than 2,000 U.S.  customers, 89 percent of buyers agree that they’re more likely to buy products from Amazon than other eCommerce sites (Feedvisor, 2019).

 

About Better Plant Sciences Inc. 

Better Plant develops and acquires intellectual property and other assets related to plant-based products and therapeutics. Through its integrated business model, Better Plant develops, manufactures, markets, sells and distributes plant-based products. It has over 200 proprietary wellness formulas at various stages of commercialization.  It operates websites and sells through eCommerce, Amazon and through a retail store network over 150 plant based products for body, baby and home under the brands JUSU, Urban Juve and Wright & Well. Its majority-owned subsidiary NeonMind Biosciences Inc. is launching a line of coffees infused with health optimizing functional mushrooms including reishi, cordyceps, lion’s mane and turkey tail mushrooms. NeonMind is also engaged in research into developing a psilocybin (psychedelic mushroom) based product for weight loss and has applied for Health Canada approval to begin preclinical trials to study its pending psychedelic medicine patents.

For more information about Better Plant, visit www.betterplantsciences.com or follow @betterplantsciences on Instagram.

 

Investor Relations Contact:

Penny White, President & CEO

Kevan Matheson, Investor Relations

invest@betterplantsciences.com

1-833-514-2677

The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.

 

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation.  Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements.  Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, brand development, availability of packaging, intellectual property protection, reduced global commerce and reduced access to raw materials and other supplies due to the spread of the Coronavirus, the potential for not acquiring any rights as a result of the patent  application and any products making use of the intellectual property may be ineffective or the company may be unsuccessful in commercializing them; and other approvals will be required before commercial exploitation of the intellectual property can happen.  Demand for the company’s products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets.  Better cautions readers not to place undue reliance on forward-looking statements provided by Better, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Better expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.